Skip to main content
. 2016 Jul 12;7(32):51651–51664. doi: 10.18632/oncotarget.10541

Figure 1. Imipramine blue (IB) decreases viable BCR-ABL1+ CML cell number in a concentration dependent manner with respect to untreated control.

Figure 1

(A) The number of viable CD34+ CML-CP cells remaining after 72 h in culture with increasing concentrations of IB, as counted by Trypan Blue dye exclusion method, was normalized to the No Drug Control (NDC) for each of three patients (solid line CML003; dashed line CML388; dotted line CML391). Minimum 5 data points per curve, curve fit r2 = 0.84, 0.97 and 0.94 for CML003, 388 and 391, respectively). (B) KCL22 cells with un-mutated (wildtype, WT) BCR-ABL1 were cultured with increasing concentration of IB and counted after 72 h (mean ± SEM of 3 repeat experiments).